Single and Multiple Ascending Dose Study of AMG 171 in Subjects With Obesity

A Phase 1, Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 171 in Subjects With Obesity

To assess the safety and tolerability of AMG 171 as single or multiple doses in subjects with obesity

Inclusion Criteria

• Males and females with ages between 18 and 65 years old, inclusive
• Except for obesity, otherwise healthy
• Body mass index (BMI) greater than or equal to 30.0 kg/m2 and less than or equal to 40.0 kg/m2 at screening
• Other Inclusion criteria may apply

Exclusion Criteria:

• Currently receiving treatment in another investigational device or drug study
• Women of childbearing potential
• History or evidence of a clinically significant disorder, condition or disease that would pose a risk to subject safety or interfere with the study evaluation, procedures or completion
• Other Exclusion criteria may apply